Immunovaccine launches clinical trial for DPX-RSV vaccine
The purpose of the study is to determine the immune response profile and safety of the DPX-RSV vaccine candidate when it is administered to healthy adults. The study requires 40 healthy adults between the ages of 50 and 64. Researchers will administer two different dose levels of the vaccine and then determine the patients’ responses.
"We are pleased to initiate this clinical trial in older adults, a largely underserved population for RSV," Canadian Center for Vaccinology Investigator Joanne Langley said. "By using a vaccine candidate formulated in DepoVax, we are hoping to generate strong immune responses in older individuals."
RSV infects the breathing passages and lungs. Those most at risk for contracting the illness are infants, the elderly and those who have compromised immune systems.
The Immunovaccine RSV vaccine candidate contains a unique target, a viral protein on the surface of infected cells.
"We developed this novel human RSV vaccine candidate in our laboratory at Ghent University and VIB (a non-profit life science research institute), and published those findings in an international scientific journal in 2014," Ghent University Professor Emeritus Xavier Saelens said. "We are very excited to see Immunovaccine engage in this clinical trial to further advance the vaccine."
RSV is the second most commonly identified cause of viral pneumonia in older persons.
"Currently, there is no vaccine available for the prevention of RSV, creating both a significant unmet medical need and a large vaccine market," Immunovaccine CEO Marc Mansour said. "A novel and effective vaccine formulated in a strongly immunogenic platform like DepoVax offers great potential for success, and we look forward to the data that will be generated in this clinical trial."